Patents by Inventor Jeremy Ian Levin

Jeremy Ian Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl Sulfonamides and Methods for Using Same
    Publication number: 20100137298
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Application
    Filed: June 13, 2008
    Publication date: June 3, 2010
    Applicant: Wyeth
    Inventors: Jeremy Ian Levin, Thomas Saltmarsh Rush, III, Frank Lovering, Yonghan Hu, Jianchang Li, Wei Li, Jun Jun Wu, Rajeev Hotchandani, Jason Shaoyun Xiang, Xuemei Du, Derek Cecil Cole, Steve Yikkai Tam
  • Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
    Publication number: 20100029657
    Abstract: Compounds of formula A: and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.
    Type: Application
    Filed: February 26, 2009
    Publication date: February 4, 2010
    Applicant: Wyeth
    Inventors: Jeremy Ian Levin, Darrin William Hopper, Nancy Torres, Minu Dhanjisha Dutia, Dan Maarten Berger, Xiaolun Wang, Martin Joseph Di Grandi, Chunchun Zhang, Alejandro Lee Dunnick
  • Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
    Patent number: 7485667
    Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: February 3, 2009
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy Ian Levin, Mila Ti Du
  • Biaryl sulfonamides and methods for using same
    Patent number: 7420001
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: September 2, 2008
    Assignee: Wyeth
    Inventors: Jeremy Ian Levin, Thomas Saltmarsh Rush, III, Frank Lovering, Yonghan Hu, Jianchang Li, Wei Li, Jun Jun Wu, Rajeev Hotchandani, Jason Shaoyun Xiang, Xuemei Du, Derek Cecil Cole, Steve Yikkai Tam
  • Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof
    Publication number: 20070219183
    Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine and dihydroimidazo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a dihydropyrazolo[1,5-a]pyrimidine or a dihydroimidazo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a dihydropyrazolo[1,5-a]pyrimidine or a dihydroimidazo[1,5-a]pyrimidine derivative.
    Type: Application
    Filed: March 15, 2007
    Publication date: September 20, 2007
    Applicant: Wyeth
    Inventors: Jeremy Ian Levin, Zhong Li, Dennis Powell
  • Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
    Patent number: 7199155
    Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: April 3, 2007
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy Ian Levin, Mila Ti Du
  • Crystalline TNF-?-converting enzyme and uses thereof
    Patent number: 6842704
    Abstract: A tumor necrosis factor-? converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: January 11, 2005
    Assignees: Immunex Corporation, Max-Planck-Institute for Biochemistry, Wyeth
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Crystalline TNF-alpha-converting enzyme and uses thereof
    Publication number: 20040265983
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 30, 2004
    Applicants: IMMUNEX CORPORATION; MAX-PLANCK-INSTITUTE FOR BIOCHEMISTRY, WYETH
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
    Publication number: 20040127524
    Abstract: Hydroxamic acids having the formula 1
    Type: Application
    Filed: December 19, 2003
    Publication date: July 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Jeremy Ian Levin, Mila Ti Du
  • 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
    Patent number: 6544984
    Abstract: Compounds having the following formula:   are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: April 8, 2003
    Assignee: American Cyanamid Company
    Inventors: Jay Donald Albright, Efren Guillermo Delos Santos, Jeremy Ian Levin, James Ming Chen
  • Crystalline TNF-alpha-converting enzyme and uses thereof
    Publication number: 20030004651
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: September 24, 2001
    Publication date: January 2, 2003
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6462073
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: October 8, 2002
    Assignee: American Home Products Corporation
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6441023
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflmatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: August 27, 2002
    Assignee: American Home Products Corporation
    Inventors: Aranapakam Mudumbai Venkatesan, Jannie Lea Baker, Jeremy Ian Levin
  • CRYSTALLINE TNF-ALPHA-CONVERTING ENZYNE AND USES THEREOF
    Publication number: 20020081692
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: February 4, 1999
    Publication date: June 27, 2002
    Inventors: ROY A. BLACK, RAYMOND JAMES PAXTON, WOLFRAM BODE, KLAUS MASKOS, CARLOS FERNANDEZ-CATALAN, JAMES MING CHEN, JEREMY IAN LEVIN
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Publication number: 20020032186
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflmatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Application
    Filed: July 3, 2001
    Publication date: March 14, 2002
    Applicant: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, Jannie Lea Baker, Jeremy Ian Levin
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Publication number: 20020006922
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Application
    Filed: July 5, 2001
    Publication date: January 17, 2002
    Applicant: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Publication number: 20010051614
    Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g.
    Type: Application
    Filed: November 29, 2000
    Publication date: December 13, 2001
    Inventors: Jeremy Ian Levin, Frances Christy Nelson
  • Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 6197795
    Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: March 6, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy Ian Levin, Frances Christy Nelson
  • N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6197791
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: March 6, 2001
    Assignee: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors
    Patent number: 6162814
    Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: December 19, 2000
    Assignee: American Cyanamid Company
    Inventors: Jeremy Ian Levin, Frances Christy Nelson